Header Logo

Connection

Philip Comp to Anticoagulants

This is a "connection" page, showing publications Philip Comp has written about Anticoagulants.
Connection Strength

0.775
  1. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: The Danaparoid Hip Arthroplasty Investigators Group. Orthopedics. 1998 Oct; 21(10):1123-8.
    View in: PubMed
    Score: 0.134
  2. Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1996 Nov 01; 78(9):1074-6.
    View in: PubMed
    Score: 0.117
  3. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9.
    View in: PubMed
    Score: 0.065
  4. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost. 2007 Sep; 5(9):1854-61.
    View in: PubMed
    Score: 0.062
  5. Anticoagulation proteins C and S. Adv Exp Med Biol. 1987; 214:47-54.
    View in: PubMed
    Score: 0.059
  6. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005 Oct; 87(10):2169-77.
    View in: PubMed
    Score: 0.054
  7. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003 Oct 30; 349(18):1703-12.
    View in: PubMed
    Score: 0.048
  8. Treatment and management of acute venous thromboembolic disease. Thromb Res. 2003; 111(1-2):3-8.
    View in: PubMed
    Score: 0.045
  9. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001 Jul 03; 104(1):74-8.
    View in: PubMed
    Score: 0.040
  10. Advances in the etiology and treatment of venous thromboembolism. Adv Intern Med. 1999; 44:59-89.
    View in: PubMed
    Score: 0.034
  11. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest. 1995 Jan; 95(1):309-16.
    View in: PubMed
    Score: 0.026
  12. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1994 Oct 01; 74(7):657-61.
    View in: PubMed
    Score: 0.025
  13. Preventing systemic embolism in patients with abnormal ventricular function. Cardiol Clin. 1994 Aug; 12(3):477-85.
    View in: PubMed
    Score: 0.025
  14. Laboratory evaluation of protein S status. Semin Thromb Hemost. 1990 Apr; 16(2):177-81.
    View in: PubMed
    Score: 0.019
  15. Traces of factor VIIa modulate thromboplastin sensitivity to factors V, VII, X, and prothrombin. J Thromb Haemost. 2006 Jul; 4(7):1553-8.
    View in: PubMed
    Score: 0.014
  16. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998 Jan 01; 128(1):1-7.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.